Company research
Tempest Therapeutics, Inc.
CIK 1544227Updated Sep 24, 2026
SecurityTPST · NASDAQ · equity
Name history
Millendo Therapeutics, Inc. · through Jul 1, 2021OvaScience, Inc. · through Dec 6, 2018
TPST price & chart
Loading TradingView…
NASDAQ:TPST on TradingView ↗About the company
We are a clinical-stage biotechnology company advancing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, including our lead program, TPST-4003, a dual-targeting CD19/B-cell maturation antigen (“BCMA”) in vivo CAR-T product candidate, which we are developing for indications in immunology and oncology. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a dual-targeting CAR-T platform, which included product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/BCMA CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma and the rare disease, POEMS syndrome.
In the news
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 ↗
Recent filings
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
DEFA14A filing
Submission of Matters to a Vote of Security Holders · Other Events
Items 5.07, 8.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
424B3 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,931,000Source | 41,488,000Source | 51,603,000Source | 46,089,000Source |
| Property, Plant and Equipment, NetUSD | 605,000Source | 886,000Source | 840,000Source | 1,060,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,707,000Source | 30,268,000Source | 39,230,000Source | 31,230,000Source |
| Assets, CurrentUSD | 8,269,000Source | 31,474,000Source | 40,363,000Source | 32,950,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 562,000Source | 1,206,000Source | 1,133,000Source | 1,270,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,540,000Source | 8,643,000Source | 9,952,000Source | 11,650,000Source |
| Other Assets, NoncurrentUSD | 517,000Source | 485,000Source | 448,000Source | 429,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 10,263,000Source | 22,362,000Source | 24,835,000Source | 27,978,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,000Source | 44,000Source | 22,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 240,031,000Source | 226,188,000Source | 192,009,000Source | 153,872,000Source |
| Retained Earnings (Accumulated Deficit)USD | -233,368,000Source | -207,106,000Source | -165,263,000Source | -135,772,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,668,000Source | 19,126,000Source | 26,768,000Source | 18,111,000Source |
| Liabilities and EquityUSD | 16,931,000Source | 41,488,000Source | 51,603,000Source | 46,089,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,314,000Source | 14,220,000Source | 9,411,000Source | 7,277,000Source |
| Operating Lease, Liability, CurrentUSD | 1,192,000Source | 869,000Source | 952,000Source | 1,413,000Source |
| Accounts Payable, CurrentUSD | 1,038,000Source | 2,450,000Source | 845,000Source | 1,108,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,949,000Source | 8,142,000Source | 9,160,000Source | 10,330,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 937,000Source | 2,726,000Source | 1,673,000Source | 2,961,000Source |
| Long-term DebtUSD | — | 6,400,000Source | 10,500,000Source | 10,400,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 6,354,000Source | 4,285,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | 6,264,000Source | 10,371,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -26,820,000Source | -33,027,000Source | -27,357,000Source | -31,072,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | -435,000Source | -170,000Source | -562,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 435,000Source | 170,000Source | 562,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,259,000Source | 24,500,000Source | 35,602,000Source | 11,403,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,150,000Source | 30,711,000Source | 39,673,000Source | 31,598,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 192,000Source | 1,177,000Source | 1,249,000Source | 1,539,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 3,118,000Source | 5,303,000Source | 2,546,000Source | 1,561,000Source |
| DepreciationUSD | 266,000Source | 389,000Source | 381,000Source | 638,000Source |
| General and Administrative ExpenseUSD | 13,969,000Source | 13,550,000Source | 11,659,000Source | 12,113,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 207,000Source | 1,316,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Nonoperating Income (Expense)USD | 313,000Source | 183,000Source | -334,000Source | -1,069,000Source |
| Other Nonoperating Income (Expense)USD | 520,000Source | 1,499,000Source | 1,115,000Source | 549,000Source |
| Proceeds from Issuance of Common StockUSD | 6,045,000Source | 28,591,000Source | 35,602,000Source | 8,861,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -26,575,000Source | -42,026,000Source | -29,157,000Source | -34,640,000Source |
| Other Nonoperating Income (Expense)USD | 520,000Source | 1,499,000Source | 1,115,000Source | 549,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Earnings Per Share, BasicUSD per share | -6.33Source | -1.5Source | -1.91Source | -3.09Source |
| Earnings Per Share, DilutedUSD per share | -6.33Source | -1.5Source | -1.91Source | -3.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,149,733Source | 27,901,739Source | 15,416,203Source | 11,548,907Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,149,733Source | 27,901,739Source | 15,416,203Source | 11,548,907Source |
| Interest Expense (non-operating)USD | 207,000Source | 1,316,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 13,969,000Source | 13,550,000Source | 11,659,000Source | 12,113,000Source |
| Interest ExpenseUSD | — | — | 1,449,000Source | 1,618,000Source |
| Nonoperating Income (Expense)USD | 313,000Source | 183,000Source | -334,000Source | -1,069,000Source |
Offerings
Registration 333-298498
Registration 333-292026
Filing attachments
d185404dex991.htm · 8-K · 2026-09-17
EX-99.1 3 d185404dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma -Early clinical observations demonstra…
Read attachment ↗d108044dex41.htm · 8-K · 2026-09-15
EX-4.1 2 d108044dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗d108044dex42.htm · 8-K · 2026-09-15
EX-4.2 3 d108044dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗tpst-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 tpst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027 Unveiled pipeline of next-generation in …
Read attachment ↗d107304dex991.htm · 8-K · 2026-07-22
EX-99.1 3 d107304dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications Senlang Biotechnology, a cli…
Read attachment ↗d91703dex991.htm · 8-K · 2026-06-04
EX-99.1 2 d91703dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors Brisbane, CA, June 4, 2026 - Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective June 4, 2026. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate fi…
Read attachment ↗